We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive ...

In a report released on January 7, Gregory Renza from RBC Capital maintained a Buy rating on MannKind (MNKD – Research Report), with a price ...

MannKind Co. (NASDAQ:MNKD – Get Free Report) has been given an average recommendation of “Buy” by the nine research firms that are currently covering the company, Marketbeat.com reports.

RBC has upgraded MannKind (NASDAQ:MNKD) to outperform from sector perform, citing the company’s Tyvaso DPI royalty revenue opportunity and orphan lung pipeline. The investment bank estimates the ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for ...

Just think about the savvy investors who held MannKind Corporation (NASDAQ:MNKD) shares for the last five years, while they gained 374%. This just goes to show the value creation that some ...